---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-216709"
form_type: "8-K"
ticker: "VRDN"
cik: "0001590750"
company_name: "Viridian Therapeutics, Inc.\\DE"
filed_at: "2026-05-11T20:02:12+00:00"
generated_at: "2026-05-11T23:03:24.743026+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Viridian raises ~$359M via $250M convertible notes and $117M equity offering

## Summary
- Issued $250M aggregate principal of 1.75% Convertible Senior Notes due 2032; initial conversion price ~$24.65/share.
- Equity offering of 7,352,942 shares at $17.00/share, netting ~$117M.
- Combined net proceeds ~$359M; to repay Hercules Capital debt, fund thyroid eye disease franchise expansion, and R&D.
- Both offerings closed May 11, 2026; underwriters' over-allotments exercised in full.
- Notes are unsecured, mature May 15, 2032, with semi-annual interest starting Nov 15, 2026.

## SEC filing metadata
- accession: 0001193125-26-216709
- form_type: 8-K
- ticker: VRDN
- cik: 0001590750
- company_name: Viridian Therapeutics, Inc.\DE
- filed_at: 2026-05-11T20:02:12+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590750/000119312526216709/0001193125-26-216709-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590750/000119312526216709/d154062d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-216709
- JSON: https://secwatch.observer/filing/0001193125-26-216709.json
- Plain text: https://secwatch.observer/filing/0001193125-26-216709.txt

## Key facts
- Debt Financings
  Viridian Therapeutics, Inc.\DE incurred convertible notes of 250,000,000 with U.S. Bank Trust Company, National Association at 1.75% maturing May 15, 2032.
  - Instrument: convertible notes
  - Principal: 250,000,000
  - Counterparty: U.S. Bank Trust Company, National Association
  - Rate: 1.75%
  - Maturity: May 15, 2032
  - Event: incurrence
  source text: On May 11, 2026, Viridian Therapeutics, Inc. (the “Company”) completed its public offering (the “Convertible Notes Offering”) of $250,000,000 aggregate principal amount of its 1.75% Convertible Senior Notes due 2032 (the “Notes”), including the exercise in full of the underwriters’ option to purchase up to an additional $25.0 million aggregate principal amount of the Notes, solely to cover over-allotments.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1590750/000119312526216709/0001193125-26-216709-index.htm
- Material Agreements
  Viridian Therapeutics, Inc.\DE entered into Indenture with U.S. Bank Trust Company, National Association valued at $250,000,000 aggregate principal amount (effective 2026-05-11).
  - Action: entry
  - Agreement: notes offering
  - Counterparty: U.S. Bank Trust Company, National Association
  - Value: $250,000,000 aggregate principal amount
  - Effective: 2026-05-11
  source text: On May 11, 2026, Viridian Therapeutics, Inc. (the “Company”) completed its public offering (the “Convertible Notes Offering”) of $250,000,000 aggregate principal amount of its 1.75% Convertible Senior Notes due 2032 (the “Notes”), including the exercise in full of the underwriters’ option to purchase up to an additional $25.0 million aggregate principal amount of the Notes, solely to cover over-allotments. The Notes were issued pursuant to, and are governed by, an indenture (the “Base Indenture”), dated as of May 11, 2026, between the Company and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”), as supplemented by a first supplemental indenture (the “Supplemental Indenture,” and the Base Indenture, as supplemented by the Supplemental Indenture, the “Indenture”), dated as of May 11, 2026, between the Company and the Trustee.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1590750/000119312526216709/0001193125-26-216709-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.